Correction to: Health-related quality of life with sacituzumab govitecan in HR+/HER2- metastatic breast cancer in the phase III TROPiCS-02 trial
- PMID: 40132065
- PMCID: PMC11935525
- DOI: 10.1093/oncolo/oyae370
Correction to: Health-related quality of life with sacituzumab govitecan in HR+/HER2- metastatic breast cancer in the phase III TROPiCS-02 trial
Erratum for
-
Health-related quality of life with sacituzumab govitecan in HR+/HER2- metastatic breast cancer in the phase III TROPiCS-02 trial.Oncologist. 2024 Sep 6;29(9):768-779. doi: 10.1093/oncolo/oyae088. Oncologist. 2024. PMID: 38748596 Free PMC article. Clinical Trial.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
